Discounts and rebates granted to public payers for medicines in european countries

Southern Med Review

Volumn 5, Issue 1, 2012, Pages 38-46

  Vogler, Sabine ^a   Zimmermann, Nina ^a   Habl, Claudia ^a   Piessnegger, Jutta ^b   Bucsics, Anna ^b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b Main Association of Austrian Social Security Institutions   (Austria)

Author keywords

Cost containment; Discount; Europe; Medicines; Payer; Policy measure; Rebate; Reimbursement; Tendering

Indexed keywords

ARTICLE; COST CONTROL; COST MINIMIZATION ANALYSIS; DISCOUNT; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EUROPE; HOSPITAL PATIENT; HUMAN; INTERNATIONAL COOPERATION; OUTPATIENT; QUESTIONNAIRE; REBATE; REIMBURSEMENT;

EID: 84864376612     PISSN: 11742704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004;329(7475):1169-72.
2. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bulletin of the World Health Organization. 2006;84:371-5.
3. Laing R, Waning B, Gray A, Ford N, t Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. The Lancet. 2003;361(9370):1723-9.
4. Quick JD, Hogerzeil HV, Velásquez G, Rägo L. Twenty-five years of essential medicines. Bulletin of the World Health Organization. 2002;80:913-4.
5. OECD. Pharmaceutical pricing policies in a global market. Paris: OECD; 2008.
6. Vogler S. Preisbildung und Erstattung von Arzneimitteln in der EU - Gemeinsamkeiten, Unterschiede und Trends. Pharmazeutische Medizin. 2012;14(1):48-56.
7. Vogler S, Habl C, Bogut M, Voncina L. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J. 2011;52(2):183-97. Epub 2011/04/16.
8. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review. 2011;4(2):32.
9. Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe? Health policy. 2011;101(2):146-52.
10. Zuidberg C. The pharmaceutical system of the Netherlands. A comparative analysis between the Dutch out-patient pharmaceutical system, in particular the pricing and reimbursement characteristics, and those of the other European Union Member States, with a special focus on tendering-like systems. Vienna: Gesundheit Österreich GmbH, 2010.
11. Dauben H-P, Stargardt T, Busse R. PPRI Pharma Profile Germany. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, 2008.
12. Ognyanova D, Zentner A, Busse R. Pharmaceutical reform 2010 in Germany. Eurohealth. 2011;17(1):11-3.
13. Leopold C, Vogler S, Habl C. Was macht ein erfolgreiches Referenzpreissystem aus? Erfahrungen aus internationaler Sicht [in German] / Implementing a successful reference price system - Experiences from other countries. Soziale Sicherheit. 2008(11):614-23.
14. Kanavos P, Seeley L, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. LSE Health, 2009.
15. Habl C, Vogler S, Leopold C, Schmickl B, Fröschl B. Referenzpreissysteme in Europa. Analyse und Umsetzungsvoraussetzungen für Österreich. Wien: ÖBIG Forschungs- und Planungsgesellschaft mbH; 2008.
16. Arickx F. The "price regulation" experience - Belgium. Presentation at the informal session "Pricing And Reimbursement Of Generic Medicines: Policy Outlook And Market Impact" organised by the European Commission, DG ENTR. 15 July 2009.
17. DeSwaef A, Antonissen Y. PPRI Pharma Profile Belgium. Vienna: Pharmaceutical Pricing and Reimbursement Information, 2008.
18. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC health services research. 2010;10:153.
19. Espín J, Rovira J, García L. Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. EMINet, 2011.
20. Kanavos P, Ferrario A, Espin J. Managed Entry Agreements for Pharmaceuticals: The European Experience. EMINet, 2011 (unpublished).
21. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Current Medical Research and Opinion. 2007;23(10):2467-76.
22. Simoens S, De Coster S. Sustaining Generic Medicines Markets in Europe. Journal of Generic Medicines. 2006;3(4):257-68.
23. Simoens S. Developing Competitive and Sustainable Polish Generic Medicines Market. Croat Med J. 2009;50(5):440-8.
24. Kanavos P, Schurer W, Vogler S. Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices. London/Vienna: 2011.
25. Simoens S. A review of generic medicine pricing in Europe. GaBI Journal. 2012;1(1):8-12.
26. Bucsics A. Current issues in drug reimbursement. Clinical Pharmacology: Current Topics and Case Studies. In: Müller M, editor.: Springer Vienna; 2010. p. 33-50.
27. Vogler S, Habl C, Leopold C, Rosian-Schikuta I. PPRI Report. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, 2008.
28. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Glossary of pharmaceutical terms.Latest update of print version: 2011; regularly updated online. Vienna 2011 [Accessed: May 5, 2012]; Available from: http://whocc.goeg.at/Glossary/Search.
29. Arts D, Habl C, Rosian I, Vogler S. Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project. Italian Journal of Public Health. 2006;3(1):41.
30. Vogler S, Espin J, Habl C. Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain. Pharmaceuticals Policy and Law. 2009(11):213-34.
31. PPRI network members. PPRI / PHIS Pharma Profiles. Available from: http://whocc.goeg.at/Publications/CountryReports:PPRI (Pharmaceutical Pricing and Reimbursement Information), 2007-2011.
32. PHIS network members. PHIS Hospital Pharma Reports. Available from: http://whocc.goeg.at/Publications/CountryReports:PHIS (Pharmaceutical Health Information System), 2009-2011.
33. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report. Vienna: Pharmaceutical Health Information System; Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, 2010.
34. Leopold C, Habl C, Rosian-Schikuta I. Steuerung des Arzneimittelverbrauchs am Beispiel Dänemarks. Buch, Monographie. Wien: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, 2007.
35. Thomsen E, Er S, Fonnesbæk Rasmussen P. PPRI Pharma Profile Denmark. Vienna: PPRI (Pharmaceutical Pricing and Reimbursement Information), 2008.
36. Heads of Medicines Agencies. Availability of Human Medicinal Products.Report of Task Force of HMA MG. Madeira: 2007.
37. Leopold C, Rovira J, Habl C. Generics in small markets or for low volume medicines European Union. Vienna: EMINet, 2010.
38. Garuoliene K, Godman B, Gulbinovi J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(3): 343-9.
39. Robertson J, Walkom EJ, Henry DA. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Australian Health Review. 2009;33(2):192-9.
40. Gray AL. Medicine Pricing Interventions - the South African experience. Southern Med Review 2009;2(2):15-9.
41. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe-A descriptive overview. Health policy. 2012;104(1):60. Epub 2011/10/22.
42. Vogler S, Zimmermann N, Leopold C, Schmickl B, Windisch F. Impact of medicines price reductions in Greece and Spain on other European countries applying external price referencing. Poster. Drug Utilisation and Health Policy Meeting; Antwerp: EuroDURG 2011.
43. Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J. PHP22 Are Hospital Medicines Prices Influenced by Discounts and Rebates? Value in Health. 2011;14(7):A337.
44. Nikou K, Perdikouri K. Critical appraisal of a new medicines pricing policy in Greek hospitals. European Journal of Hospital Pharmacy: Science and Practice. 2012;19(2):130.
45. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet. 2009;373(9659):240-9.
46. WHO, Health Action International (HAI). Medicine Prices. A new approach to measurement. Working draft for field testing and revision. 2003.
47. WHO, Health Action International (HAI). Measuring medicine prices, availability, affordability and price components. 2nd edition. Geneva, 2008.